Breast Cancer Clinical Trials in Philadelphia

Showing 181-200 of 673 trials

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more

Janux Therapeutics130 participantsStarted Apr 2023

Duarte, California, United States • Sacramento, California, United States • San Diego, California, United States +15 more locations

COMPLETEDPhase 1< 1 mile

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

CardiotoxicityRisk Factor, CardiovascularToxicity Due to Chemotherapy+3 more

Abramson Cancer Center at Penn Medicine68 participantsStarted Aug 2019

Philadelphia, Pennsylvania, United States

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Breast Cancer Trials in Other Cities

African Cancer Genome: GMD

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Other Conditions in Philadelphia